Evotec SE (EVO)
Nasdaq: EVO · Pharmaceutical Preparations · Hamburg, DE · filing with the SEC since 2007
Who owns Evotec SE
As filed with the SECHolders of 5% or more
2
Excalibur LuxCo SARL holds 9.99% of Ordinary Shares, no par value per share, as its SCHEDULE 13D/A filed Oct 29, 2025 says.
Directors and officers
0
report now, of 0 people on the record since . Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Excalibur LuxCo SARL
SCHEDULE 13D/A · filed Oct 29, 2025 · Ordinary Shares, no par value per share
MAK Capital Fund LP
SCHEDULE 13D/A · filed May 1, 2026 · Ordinary Shares, no par value per share · 7% in Apr 6, 2026
Mubadala Investment Company PJSC
SCHEDULE 13D/A · filed Oct 14, 2026 · Ordinary Shares, no par value per share · reported falling below 5%
Novo Holdings A/S
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, no par value per share · reported falling below 5%, from 5.3% in Nov 14, 2025
What EVO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Just-Evotec Biologics EU SAS, Toulouse, France
An entity · subsidiary · owns, named in the 20-F filed Apr 8, 2026
Centauri Therapeutics GmbH
An investee · associate · invested in, named in the 20-F filed Apr 8, 2026
Dark Blue Therapeutics LTD, Oxford, United Kingdom
An investee · associate · invested in, named in the 20-F filed Apr 8, 2026
EIR Biotherapies S.r.l., Mirandola (MO), Italy
An investee · associate · invested in, named in the 20-F filed Apr 8, 2026
Quantro Therapeutics GmbH, Wien, Austria
An investee · associate · invested in, named in the 20-F filed Apr 8, 2026
Topas Therapeutics GmbH, Hamburg, Germany
An investee · associate · invested in, named in the 20-F filed Apr 8, 2026
18 subsidiaries in 8 countries, from the list filed with the 20-F filed Apr 8, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.